ABQ Times

Researchers at The University of New Mexico Comprehensive Cancer Center are making notable advancements in the fight against cancer through various innovative projects. In a recent episode of a podcast titled "One Step Closer to a Cure for Cancer," UNM gynecologic oncologist Dr. Sarah Adams discussed some promising developments in the field, including a "zombie vaccine" and a new clinical trial model.

Dr. Adams, alongside materials scientist Rita Serda, has developed a new cancer vaccine using tumor cells coated in silica. Adams explained, "The cells are dead on the inside, but look the same on the outside. That coating allows us to teach the immune system what to attack." This vaccine, which has shown positive results in mice with ovarian and colon cancer, could soon enter human clinical trials. The shelf-stable nature of the vaccine allows it to be dehydrated and stored at room temperature, addressing a significant barrier to global accessibility.

The UNM Comprehensive Cancer Center is also revamping clinical trial models under the leadership of researchers like Dr. Ursa Brown-Glaberman. The center is taking trials out of Albuquerque and into the broader community, significantly easing patient access. Adams remarked, "Patients used to drive six hours just to access trials in Albuquerque. Now we're bringing the treatments to them." This decentralized model, supported by national recognition, includes regular communication between UNM researchers and local oncologists to facilitate trials and reduce healthcare disparities in rural areas.

Adams noted an evolving focus in clinical trials from the "maximum tolerated dose" to the "maximum effective dose" of treatments, aiming to balance effectiveness with minimal toxicity. This reflects a broader trend toward pragmatic clinical trials, characterized by greater flexibility and speed in treatment delivery.

Artificial intelligence is also being harnessed by Dr. Avinash Sahu, a recent recruit from Harvard. Dr. Sahu is implementing AI to match patients with suitable treatments based on their tumor's genetic traits. This approach holds the potential to optimize patient outcomes and expedite clinical trial enrollment.

UNM is also initiating a data commons project with RS21 to investigate environmental and geographic cancer risks specific to New Mexico. Additionally, the center is spearheading a federally funded uterine cancer research project, focusing on developing new hormone therapies and fertility-preserving treatments for young women.

Adams emphasized the center’s mission, saying, "We want all of our research to serve the people who come through our doors. That's the whole point."

More details on these initiatives can be heard in the podcast "It's (Probably) Not Rocket Science," available on various platforms.